Background {#Sec1}
==========

Cisplatin (CP) is a chemotherapy commonly used in cancer treatment including head, neck, ovarian, and testicular cancers \[[@CR1], [@CR2]\] but is associated with nephrotoxicity in 28--36% of patients receiving an initial dose (50--100 mg/m^2^) of cisplatin \[[@CR3]\]. The accumulation of high concentrations of cisplatin in the kidneys caused nephrotoxicity \[[@CR4]\]. This serious complication is contributed to limiting its clinical use. The intermission of cisplatin remains the only choice in the case of progressive renal failure \[[@CR5]\]. Cisplatin-induced nephrotoxicity through apoptosis and necrosis \[[@CR6]\], vascular factors \[[@CR7]\], and inflammation of the tubules \[[@CR8]\]. The development of renal tubule injury is caused by the oxidative stress induced by cisplatin \[[@CR9]--[@CR12]\]. The reactive oxygen species (ROS) and reactive nitrogen species (RNS) production \[[@CR13]\] alter the structure and function of cellular membranes \[[@CR14]\]. In addition to their accumulation in kidney and lysosomes \[[@CR15]\] explained the mechanisms for CP-induced acute nephropathy \[[@CR13]\]. Although numerous mechanisms for CP-induced nephrotoxicity such as mitochondrial dysfunction, inflammation, DNA damage, oxidative stress and apoptosis had been studied, the precise mechanism is not well understood \[[@CR16], [@CR17]\]. Therefore, the free radical scavengers and the antioxidants agent can prevent cisplatin-induced nephrotoxicity.

Cisplatin damages the DNA resulting in apoptosis induction \[[@CR18]\]. In response to cisplatin, several signaling pathways, which can be activated by lipid peroxidation and oxidative stress, modulate the cell survival or apoptosis \[[@CR18], [@CR19]\]. The mitogen-activated protein kinase (*MAPK*) pathways regulate differentiation, proliferation, apoptosis and are activated by chemical and physical stresses \[[@CR20]\]. The three major *MAPK* pathways terminate in *ERK*, *p38*, and *JNK/SAPK* enzymes. Cisplatin is known to activate these three pathways in various cell lines including renal epithelial cells \[[@CR21], [@CR22]\]. *p38 MAPK* was involved in inflammation, cell cycle regulation, and differentiation \[[@CR23]\] but its role in cancer therapy is not clear. Recently, some investigator suggests that *p38 MAPK* is able to control the p53-mediated response to cisplatin \[[@CR24]\].

The interleukin-1 *(IL-1*) made up of 11 proteins encoded by 11 different genes \[[@CR25]\] and its main function, in response to tissue injury or damage, is to control the pro-inflammatory reactions \[[@CR26]\]. Activation of *IL-1* lead to activation of some genes such as Mitogen-activated protein kinase kinase 4 (*MKK4*) and (*MKK7*) which activate *JNK* \[[@CR27], [@CR28]\], and *MKK4*, *MKK3*, and *MKK6* activate *p38 MAPK* \[[@CR29]\].

Flavonoids are a group of natural poly-phenolic compounds found in plants and have a variety of biological effects and play important role in detoxification of free radicals \[[@CR30]\]. Rutin is flavonoid glycosides that are present in herbs and plant foods and possessed different protective effects in vitro as well as in vivo \[[@CR31], [@CR32]\] against lipid peroxidation and oxidative stress-mediated diseases \[[@CR33]\]. Rutin is an immuno-modulator and has anti-oxidant, anti-diarrheal, anti-tumor, and anti-inflammatory effect, myocardial protection, and has renal protective effects against the ischemia-reperfusion-induced renal injury \[[@CR34]\]. Therefore, this study investigated the possible protective effects of rutin against cisplatin-induced nephrotoxicity in rats.

Methods {#Sec2}
=======

Animals {#Sec3}
-------

The study was approved by the Research Ethics Committee of the College of Pharmacy, King Saud University. Male Wistar rats (230--260 g) were obtained from College of Pharmacy, King Saud University Animal Care Center and were kept under standard conditions of temperature (22 ± 1 °C), humidity (50--55%), and a 12-h light:/dark cycle. Food and water were freely available. All methods were conducted in accordance with the Guide for Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, National Institute of Health (NIH publication No. 80--23; 1996).

Chemicals {#Sec4}
---------

Cisplatin (1 mg/ml sterile concentrate) was a gift from King Khalid University Hospital drug store, KSU, KSA. Rutin (CAS Number 207671-50-9) was purchased from Sigma Chemicals (Sigma-Aldrich Louis, MO, USA). Primers were designed using primer express 3 software (Applied Biosystem, Life Technologies, Grand Island, NY, USA) and Syber Green master mix kit (Cat\#4309155) were purchased from Applied Biosystems (Life Technologies, Grand Island, NY, USA).

Experimental design {#Sec5}
-------------------

The experimental Design follows Kamel et al., \[[@CR3]\]. The rats were randomly divided into four groups (ten rats each) as follows: Group-I: intraperitoneal (i.p.) received saline (2.5 ml/kg) (normal control group). Group-II: i.p. received single dose 5 mg/kg cisplatin, (cisplatin group) \[[@CR35]\]. Group-III: orally received 30 mg/kg rutin dissolved in water for 14 days (Rutin group) \[[@CR36]\]. Group-IV: orally received 30 mg/kg rutin, dissolved in water for 14 days with a single dose of cisplatin (5 mg/kg, i.p.) on the tenth day.

All animals were weighted and were exposed to ether and were killed by decapitation 24 h after the last treatment. Blood samples were obtained and sera were separated. The kidney was immediately removed then washed with ice-cold saline solution. Parts of both kidneys were cut into small pieces for histopathological study and for the gene expression analysis.

Bioassays {#Sec6}
---------

### Determination of blood urea nitrogen and serum creatinine {#Sec7}

Blood urea nitrogen (BUN) was measured spectrophotometrically according to the methods of Tobacco et al. \[[@CR37]\]. In brief, serum was diluted 1:4 in normal saline and 5 μL of diluted serum and standard (in duplicate) were added to the microplate wells; then 150 μL of urease Mix solution was added to each well. The plate was incubated for 15 min under shaking at room temperature. Then 150 μL of Alkaline Hypochlorite was added to each well. After 10 min' incubation at room temperature. Measure the absorbance of each sample in duplicate at 620 nm using microplate reader. The blood urea nitrogen concentration was calculated from stander curve. Serum creatinine was measured according to the methods of Fabiny and Ertingshausen \[[@CR38]\] in brief, 100 μl of serum samples and standard was mixed with picric acid (17.5 mmol/l final concentration)/sodium hydroxide solution (0.16 mol/l final concentration) after 30 s and 2 min later the absorbance of standard and sample were recorded. After that, the creatinine concertation was calculated by dividing the delta absorbance of the sample by delta absorbance of the control multiply by standard concentration.

Histopathology examination {#Sec8}
--------------------------

The kidneys harvested from each groups were fixed in 10% neutral buffered formaldehyde. Tissues dehydration, clearing in xylene and paraffin embedding was done according to the standard method. Sections were cut by a rotary microtome at 5--7 μm thick, and were stained by haematoxylin and eosin and periodic acid schief (PAS). Sections were examined under a light microscope and findings documented by two certified histopathologists.

Estimation of Malondialdehyde of lipid peroxidation {#Sec9}
---------------------------------------------------

Malondialdehyde (MDA) concentration in tissues was measured as it is the major product of membrane lipid peroxidation as a previously described method by Ohkawa et al., \[[@CR39]\]. The principle of this method depends on the formation of pink color resulted in reaction between MDA and thiobarbituric acid. This reaction producing a thiobarbituric acid reactive substance (TBARS), pink color, measured spectrophotometrically at 532 nm.

Estimation of (glutathione) GSH levels in kidney tissues {#Sec10}
--------------------------------------------------------

Glutathione concentration in 200 g kidney tissues homogenate was determined as previously described method by Sedlak and Lindsay \[[@CR40]\].

RNA extraction and Gene expression studies {#Sec11}
------------------------------------------

Total RNAs were extracted from kidneys tissue by Trizol method according to the manufacturer's protocol as previously described \[[@CR41]\]. The quantity was characterized using a UV spectrophotometer. The isolated RNA has an A 260/280 ratio of 1.9--2.1.

cDNA synthesis and real-time PCR methods {#Sec12}
----------------------------------------

One microgram of total RNA was used to generate cDNA using a SuperScript™ first-strand synthesis system kit (Invitrogen, CA, USA), according to the manufacturer's instructions. Real-time PCR was done using 2^-ΔΔC*t*^ method according to our previous study \[[@CR42]\] and *GAPDH* gene was used as internal control. All primers used in this study were synthesized in Jena Bioscience Germany and were listed in Table [1](#Tab1){ref-type="table"}.Table 1Primers used in this studyGene NameForward primerReverse primer*JNK*5′-AAATAGAGCATCCCAGTCTTCGA-3′5′-ACTGGGCCGCTGTTTCTG-3′*MKK4*5′- CATCGGGCCTCCAGCTT -3′5′- AAATTCAACTTCAGGGCTTTGC -3′*MKK7*5′- AAGCTCTGTGACTTTGGCATCA -3′5′- CAGCCAGCACTCCGTGTTT -3′*P38*5′-GGTTTTGGACTCGGATAAGAGGAT-3'5′-GGGTCGTGGTACTGAGCAAAG-3'*TRAF2*5′-ACGCTGCCCGCAGAGA-3'5′-TCTTTCAAGGTCCCCTTCCA-3'*TNF-α*5′-CGGGCTCAGAATTTCCAACA-3'5′-CGCAATCCAGGCCACTACTT-3'*IL-1-α*5′-CATCCGTGGAGCTCTCTTTACA-3'5′-TTAAATGAACGAAGTGAACAGTACAGATT-3'*GAPDH*5′-AACTCCCATTCCTCCACCTT-3'5′-GAGGGCCTCTCTCTTGCTCT-3'

Statistical analysis {#Sec13}
--------------------

The data were analyzed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical significance was evaluated by one-way analysis of variance (ANOVA) followed by the Tukey-Kramer multiple comparison tests. All data were expressed as mean ± SEM, *n* = 10. The value of *P* \< 0.05 was considered statistically significant.

Results {#Sec14}
=======

Effects of CP on renal cells {#Sec15}
----------------------------

The effects of CP and rutin on histological changes in kidney tissues are shown in Fig. [1](#Fig1){ref-type="fig"}. The harvested kidneys from the control and treated rat kidneys were studied under a light microscope. The four compartment in the kidney, namely, glomeruli, tubules, interstitium and blood vessels were examined for any histopathological findings. The kidney in the control rats (GI) showed no histopathological abnormality in the glomeruli, tubules, interstitium and blood vessels (Fig. [1a](#Fig1){ref-type="fig"} and [b](#Fig1){ref-type="fig"}). Rats treated with rutin dissolved in water (GII) also showed normal histology with no histopathological findings (Fig. [1c](#Fig1){ref-type="fig"}). The kidneys treated with Cisplatin showed histopathological abnormality in the interstitium and the tubules infiltrate (Fig. [1d](#Fig1){ref-type="fig"} to [h](#Fig1){ref-type="fig"}). The interstitium showed patchy mild chronic mononuclear lymphoplasmacytic inflammatory cell infiltrate and mild congestion. The tubules showed patchy acute tubular injury with reactive/ reparative atypia of the tubular epithelial cells. Some tubular epithelial cells also showed cytoplasmic vacuolization and apoptosis. The glomeruli and the blood vessels were not affected. Rats treat with Rutin and Cisplatin combination showed only minimal histopathological findings in the form of minimal interstitial congestion and minimal tubular injury in a few tubules. The glomeruli and the blood vessels appeared normal.Fig. 1Histological changes in renal tissues in response to cisplatin, rutin, and cisplatin plus rutin: **a** and **b**: photomicrographs of control rat kidney shows normal looking glomeruli (*arrows*) and the tubules (*arrowheads*) with no histological abnormality (hematoxylin-eosin stain, original magnification: ×200 and ×400 respectively). **c**: photomicrograph of rat kidney treated with rutin also show no significant pathological changes. **d**, **e** and **f**: photomicrographs of rat kidney treated with Cisplatin shows patchy lymphoplasmacytic mononuclear chronic inflammatory cell infiltrate in the interstitium (arrows) and patchy mild acute tubular epithelial cell injury (*arrowheads*) and scattered congested interstitial capillaries (hematoxylin-eosin stain, original magnifications: ×200, ×400 and ×400 respectively). **g** and **h**: more photomicrographs of rat kidney treated with Cisplatin showing reactive/reparative atypia of the injured tubular epithelial tubular cell in the form of enlarged nuclei and prominent nucleoli (*arrow*), many apoptotic tubular epithelial cells (*arrowheads*) along with focal cytoplasmic vacuolization the tubular epithelial cells (asterisk) (hematoxylin-eosin stain, original magnifications: ×400 and ×400 respectively). **i**: photomicrographs of rat kidney treated with Cisplatin and Rutin combination shows minimal focal tubular injury of few tubules (*arrows*) and minimal congestion of the interstitial capillaries (arrowhead) (hematoxylin-eosin stain, original magnification: ×400)

Effect of CP on the body weight of rats {#Sec16}
---------------------------------------

Figure [2](#Fig2){ref-type="fig"} showed the effect of Cisplatin, rutin and their combination on the rat body weight. At the end of the experiment, CP-treated animals significantly lost weight compared to control group (*P \< 0.05*). However, administration of rutin alone resulted in an increase in the body weight compared to both control and cisplatin group. Interestingly, administration of rutin in combination with CP resulted in a significant increase the body weight compared to CP group (*p \< 0.05*).Fig. 2Represent the effect of CP alone, Rutin alone and their combination on the rat body weight. Data were presented as mean ± SEM (*n* = 10). \* indicate significant change from control, \# indicate significant changes from rutin and \$ indicate a significant change Cisplatin plus Rutin

Effects of CP on renal blood urea nitrogen and serum creatinine {#Sec17}
---------------------------------------------------------------

Blood urea nitrogen (Fig. [3a](#Fig3){ref-type="fig"}) and serum creatinine (Fig. [3b](#Fig3){ref-type="fig"}) were used as biochemical markers for the nephrotoxicity. CP significant increased the levels of BUN (128.6 ± 44 mg/dl) and serum creatinine (4.6 ± 0.34 mg/dl), compared to control group 37 ± 2.4 mg/dl and 1.2 ± 0.1 mg/dl respectively *(p \< 0.001*). The rutin group showed no significant changes in BUN and serum creatinine compared to control group. However, administration of rutin in combination with CP resulted in complete reversal of CP-induced increase in BUN and serum creatinine to their normal values as in control group.Fig. 3Represents the changes in the levels of serum BUN (**a**) and creatinine (**b**) in rats. Data were presented as mean ± SEM (*n* = 10). \* indicate significant change from control, \# indicate significant changes from rutin

Assessment of renal oxidative stress {#Sec18}
------------------------------------

Oxidative stress-induced free radicals that reacted with membrane phospholipids resulted in lipid peroxidation. To investigate the effect of CP, rutin and their combination on the lipid peroxidation biomarkers the MDA level was measured. Cisplatin significantly increased MDA levels in kidney tissue by 230 ± 5.5 nmol/g compared to 68 ± 2.1 nmol/g in control group (*P \< 0.001*). Interestingly, the administration of rutin before cisplatin resulted in a reversal of MDA level induced by CP to its normal values as in control group. Administration of rutin alone showed non-significant changes in MDA levels (70 ± 1.8 nmol/g) compared to control group. Also, the free radicals depleted the antioxidant defense GSH. Rats treated with CP had a significant decrease in GSH level by 25 ± 6.8 nmol/100 mg tissue compared to 102 ± 3.5 nmol/100 mg tissue in control group. On the other hand, the administration of rutin before CP lead to increase in the GSH levels from 25 ± 6.8 nmol/100 mg tissue in CP group to 120 ± 3.6 nmol/100 mg tissue (*p \< 0.05*). Administration of rutin alone showed non-significant changes in MDA levels 107 ± 2.3 nmol/100 mg tissue compared to the control group.

The effect of CP on the gene expression levels {#Sec19}
----------------------------------------------

To investigate the effect of CP on oxidative stress genes expression levels of *IL-1α* was measured in kidney tissues by using real-time PCR (Fig. [4](#Fig4){ref-type="fig"}). CP alone was significantly increased the expression level of *IL-1α* in kidney tissues by 260% (*P \< 0.05*) and 164% (*P \< 0.001*) compared to control and rutin groups respectively. Interestingly, administration of rutin to CP-treated rats resulted in a complete reversal the reduction of *IL-1α* expression level induced by CP to control values. This reversal change was resulted in significant decrease in *IL-α* expression level by 63% (*p \< 0.007*) compared to CP group and by 73% compared to control group.Fig. 4Represents the changes in the expression level of *IL-1α* in Rat kidney tissues induced by CP. Data were presented as mean ± SEM (*n* = 10). \* indicate significant change from control, \# indicate significant changes from rutin and \$ indicate a significant change Cisplatin plus Rutin

Figure [5](#Fig5){ref-type="fig"} showed the effect of CP, rutin and their combination on *TRAF2* expression level in Rat kidney tissues. Cisplatin alone significantly increased the expression level of *TRAF2* in kidney tissues by 491% compared to control group (*P \< 0.001*). However, administration of rutin alone resulted in insignificant increase in *TRAF2* expression level by 77% compared to control groups (*P \> 0.5*). Interestingly, administration of rutin in combination with CP resulted in significant decrease in the expression level of *TRAF2* compared to CP group (*p \< 0.002*).Fig. 5Represents the changes in the expression level of *TRAF2* in Rat kidney tissues induced by CP. Data were presented as mean ± SEM (*n* = 10). \* indicate significant change from control, \# indicate significant changes from rutin and \$ indicate a significant change Cisplatin plus Rutin

Figure [6](#Fig6){ref-type="fig"} showed the effect of CP, Rutin and their combination on the expression levels of *P38* in rat kidney tissues. Treatment of CP alone resulted in significant increase in the *P38* expression level by 410% (*P \< 0.001*) in kidney tissues compared to control group. Administration of rutin alone resulted in insignificant increase in the *P38* expression levels by 38% compared to control group (*P \< 0.5*). Administration of rutin in combination with CP resulted in significant decrease in the P38 expression level compared to both control and CP groups (*P \< 0.001*).Fig. 6Represents the changes in the expression level of *P38* in Rat kidney tissues induced by CP. Data were presented as mean ± SEM (*n* = 10). \* indicate significant change from control, \# indicate significant changes from rutin and \$ indicate a significant change Cisplatin plus Rutin

Figure [7](#Fig7){ref-type="fig"} showed the effect of CP, Rutin and their combination on the expression level of *MKK4* (A), *MKK7* (B) and *JNK* (C) in kidney tissues. CP alone resulted in significant increase in MKK4 expression level by 236% (*P \< 0.001*) in *MKK7* by 412% and in *JNK* by 680% *(P \< 0.001*) compared to control group. Interestingly, rutin administration in combination with CP resulted in complete reversal of CP-induced increasing in the expression levels of both *MKK4* and *MKK7* to their normal levels as in control group. On the other hand rutin administration in combination with CP resulted in significant decrease in the expression levels of *JNK* by 71% compared to CP group. There were no significant changes observed in both *MKK4* and *MKK7* in rutin group.Fig. 7Represents the changes in the expression level of *MKK4* (**a**), *MKK7* (**b**) and *JNK* (**c**) in Rat kidney tissues. Data were presented as mean ± SEM (*n* = 10). \* indicate significant change from control, \# indicate significant changes from rutin and \$ indicate a significant change Cisplatin plus Rutin

Figure [8](#Fig8){ref-type="fig"} showed the effect of CP, Rutin and their combination on the expression level of *TNF-α* in kidney tissues. CP alone was resulted in significant increase in *TNF-α* expression level by 300% (*P \< 0.001*) compared to control group. Interestingly, rutin administration in combination with CP was resulted in complete reversal of CP-induced increasing in the *TNF-α* expression levels to its normal levels as in control group. There were no significant changes observed in *TNF-α* in rutin group.Fig. 8Represents the changes in the expression level of *TNF-α* in Rat kidney tissues. Data were presented as mean ± SEM (*n* = 10). \* indicate significant change from control, \# indicate significant changes from rutin and \$ indicate a significant change Cisplatin plus Rutin

Discussion {#Sec20}
==========

Cisplatin is an anticancer drug used in the treatment of many types of cancer such as head and neck, lung, testis, ovary, and breast cancers \[[@CR1], [@CR2]\]. Nephrotoxicity is the dose-limiting side effect of cisplatin \[[@CR43]\] such as acute kidney injury was found in about 20--30% of patients receiving CP \[[@CR44]\], Hypo-magnesemia in about 40--100% of patients \[[@CR45]\], Fanconi-like syndrome, distal renal tubular acidosis, hypo-calcemia, renal salt wasting and hyper-uricemia \[[@CR46]\].

Nephrotoxicity induced by CP is characterized by a reduction in renal function that leads to increasing in serum creatinine and blood urea levels \[[@CR47]\]. In the current study, creatinine and BUN serum levels were significantly high in CP-treated rats compared to untreated rats suggesting that CP produced nephrotoxicity as evidenced by the glomerular filtration rate reduction. The elevated serum creatinine and BUN levels induced by CP were significantly restored to their normal levels as in control group by rutin. The rutin protective effect against nephrotoxicity can be attributed to its antioxidant and anti-inflammatory effect on ROS and some cytokines may be involved in the glomerular filtration rate damage \[[@CR48]\]. Although the accurate mechanism of CP-induced nephrotoxicity is not well understood, previous study suggested that cisplatin interacts with DNA, through the formation of covalent adducts between certain DNA bases and the platinum compound leading to cell cytotoxicity \[[@CR49]\]. Other studies suggest that CP-induced ROS and immune response which are mediators of nephrotoxicity \[[@CR50]--[@CR52]\]. In the present study, the MDA and GSH were measured as biomarkers for the oxidative stress. In the kidney tissue, the MDA level was significantly increased and GSH level was decreased by the effect of cisplatin. However, rutin administration caused significant decreases in lipid peroxidation and promoted increases in GSH content in the kidney. Therefore, rutin can protect the kidney from CP-induced injury via improvement in oxidant status. A similar study found that rutin pre-treatment attenuates renal inflammation and apoptosis induced by cisplatin through reducing TNF-α, NF~k~B and caspase-3 levels \[[@CR18], [@CR25]\].

The p38-MAPK stress pathway, stimulated with inflammatory cytokines such as TNF-α or IL-1, act as a key regulator of apoptosis in cells \[[@CR53]\]. The expression of the number of inflammatory cytokines and chemokines is increased in the kidney after cisplatin injury \[[@CR54]\]. In the present study, CP increased the expression levels of both *TNF-α* or *IL1-α*. Similarly, other study found that the single injection of cisplatin in mice induced nephrotoxicity. In the kidneys of cisplatin-treated mice, the nephrotoxicity caused up-regulation in *TNF-α, IL-1β,* macrophage inflammatory protein-2 (*MIP-2*), monocyte chemoattractant protein-1 (*MCP-1*), *ICAM-1*, and *TGF-β* \[[@CR55]\].

The present study showed that the rutin supplementation improved the CP-induced increased in the expression levels of *IL-1* and *TNF-α* that were in agreement with previous reports. Rutin acts as antioxidant and anti-inflammatory and improves renal abnormality induced by several factors or chemotherapeutic agents like doxorubicin or cisplatin \[[@CR56]--[@CR58]\]. *TNF-α* induced by cisplatin is highly dependent upon the production of ROS, activation of *NFκB*, and *p38 MAPK*. However, the activation of *TNF-α* and *IL-1* are involved in several signal transduction mechanisms, including the *NF* ~*K*~ *B* and AP-1 pathways. In fact, the stress-activated group of MAPKs (*JNK* and *p38*) is strongly activated by *TNF-α* and *IL-1* \[[@CR54]\]. This was in agreement with the present study in which single dose of CP increase the expression levels of *JNK* and *P38*. The activation of *JNK* by *TNF-α* mediated by the TNF receptor-associated factor (*TRAF*) group of adapter proteins \[[@CR59]\].

In the current study, the overexpression of *TRAF2* as a result of cisplatin may be the cause of nephrotoxicity and apoptosis. The decrease in the expression level of *TRAF2* in kidney tissues after rutin supplementation in CP-treated rats suggests that rutin may protect against CP-induced nephrotoxicity by regulating apoptotic pathways. Activation of TNF receptors leads to recruitment of the *TRAF2* adapter protein \[[@CR60], [@CR61]\]. The activation of the *TRAF2* expression is required for *JNK* activation by *TNF* \[[@CR62]\]. A study showed that in nephrotoxicity induced by chemotherapy, genes for *JNK* play an essential role in modulating the pro- and anti-apoptotic proteins located in the mitochondria \[[@CR63]\]. *JNK* with ROS can promote apoptosis by inhibiting anti-apoptotic proteins \[[@CR64]\]. Also, *JNK* can be activated through its phosphorylation by *MKK4* and *MKK7* at threonine, tyrosine. *MAPKKK* activate both *MKK4* and *MKK7* protein kinases by dual phosphorylation at two sites in the T-loop \[[@CR65]\]. The *MKK*7 protein kinase is primarily activated by cytokines (e.g *TNF-α* and *IL-1*) and *MKK4* is primarily activated by environmental stress \[[@CR66]\]. In the current study CP- induced the expression levels of *MKK4* and *MKK7* and these alterations attenuated by rutin supplementation in CP-treated rats. P38 MAPK is activated by *MKK3, MKK4* and *MKK6* \[[@CR67]\]. In the present study, *P38* expression levels were increased after a single dose of cisplatin. Similarly, several studies suggested that the inhibition of *p38 MAPK*, *ERK* or *JNK* with specific pharmacologic or genetic inhibitors reduced inflammation and renal injury \[[@CR17], [@CR68], [@CR69]\].

Rutin administration in CP-treated rat restored the expression levels of *P38* and reduced the apoptosis. Therefore, cisplatin-induced nephrotoxicity can be ameliorated by free radical scavengers \[[@CR70]\], iron chelators \[[@CR71]\], superoxide dismutase \[[@CR48]\] and Vitamin E \[[@CR72]\].

Conclusions {#Sec21}
===========

In conclusion, single dose of cisplatin-induced nephrotoxicity through the activation of *P38 MAPK* pathway. Our data may help in understanding the molecular mechanisms of rutin in CP nephrotoxicity. Rutin attenuates CP nephrotoxicity might be through its antioxidant as well as *p38-MAPK* inhibitor properties.

*AP-1*

:   Activator protein 1

BUN

:   Blood urea nitrogen

CDNA

:   Complementary deoxynucleic acid

CP

:   Cisplatin

*GAPDH*

:   Glyceraldehyde-3-phosphate dehydrogenase

GSH

:   Glutathione

*IL-1-α*

:   interleukin-1 alpha

*JNK*

:   c-Jun N-terminal kinases

*MAPK*

:   Mitogen-activated protein kinase

*MCP-1*

:   Monocyte Chemoattractant protein-1

MDA

:   Malondialdehyde

*MIP2*

:   Macrophage inflammatory protein-2

*MKK4*

:   Mitogen-activated protein kinase 4

*MKK7*

:   Mitogen-activated protein kinase 7

*NF*~*k*~*B*

:   Nuclear factor kappa beta

*P38*

:   P38 mitogen-activated protein kinases

*RANTES*

:   Regulated on Activation Normal T Expressed and Secreted

RNA

:   Ribonucleic acid

RNS

:   Reactive Nitrogen Species

ROS

:   Reactive oxygen species

TBARS

:   Thiobarbituric acid reactive substance

*TGF-β*

:   Transforming growth factor-beta

*TNF-α*

:   tumor necrosis factors alpha

*TRAF2*

:   TNF Receptor-Associated Factor 2

UV

:   Ultraviolet

Authors thank the Deanship of Scientific Research at KSU for funding this work through the research group project no. RGP-142.

Funding {#FPar2}
=======

This work was funded by the Deanship of Scientific Research at KSU (research group project no. RGP-142).

Availability of data and materials {#FPar3}
==================================

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Authors' contributions {#FPar4}
======================

ARA Participate in the study design, treatment, practical work, collated, analyzed and interpreted the data, and also drafted the manuscript. MMH participated in the study design and treatment, participated in practical work, collated, analyzed and interpreted the data, and also drafted the manuscript. SH shared in the study design and treatment and participated in histopathological work, interpreted the histopathological data, and also drafted the manuscript. AMA shared in the study design and treatment and participated in histopathological work, interpreted the histopathological data, and also drafted the manuscript. MRA shared in the study design and treatment, participated in practical work, collated, analyzed and interpreted the data, and also drafted the manuscript. SSA participated in the study design and treatment, participated in practical work, collated, analyzed and interpreted the data, and also drafted the manuscript. MAA participated in the study design and treatment, participated in practical work, collated, analyzed and interpreted the data, and also drafted the manuscript. MMA participated in the study design and treatment, participated in practical work, collated, analyzed and interpreted the data, and also drafted the manuscript. OAA participated in the study design and treatment, participated in practical work, collated, analyzed and interpreted the data, and also drafted the manuscript. All authors read and approved the final manuscript.

Competing interests {#FPar5}
===================

The authors declare that they have no competing of interests.

Consent for publication {#FPar6}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar1}
==========================================

The study was approved by the Research Ethics Committee of the College of Pharmacy, King Saud University, and Riyadh, Saudi Arabia.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
